Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.

Competing Interests: Conflict of Interest statement Y.Y. and M.A. report grants from AMED related to this work. Outside of this work, Y.Y. received a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and personal fees from Kyowa Kirin, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Maruho, AbbVie, Novartis, Celgene, Eli Lilly, LEO Pharma, Sanofi and Torii Pharmaceutical Co. Outside of this work, Y.W. received personal fees from Eli Lilly, Abbvie and Novartis. Outside of this work, M.A. received grants from the Japan Agency for Medical Research and Development and the Ministry of Education, Culture, Sports, Science and Technology and personal fees from Kyowa Kirin, Maruho, Mitsubishi Tanabe Pharma Corporation, TAIHO Pharmaceutical CO., LTD, Sanofi, Novartis, Torii Pharmaceutical Co, Celgene, Astellas Pharma and Janssen Pharmaceutical KK. Others had no conflict of interest to declare.